Targeting metabotropic glutamate receptor 4 for cancer immunotherapy.

Targeting metabotropic glutamate receptor 4 for cancer immunotherapy.
复制标题

DOI:
10.1126/sciadv.abj4226
复制
发表时间:
2021-12-10
期刊:
影响因子:
13.6
通讯作者:
Li S
Li S
中科院分区:
综合性期刊1区
文献类型:
--
作者:
Wan Z;Sun R;Liu YW;Li S;Sun J;Li J;Zhu J;Moharil P;Zhang B;Ren P;Ren G;Zhang M;Ma X;Dai S;Yang D;Lu B;Li S

文献摘要

参考文献

被引文献

相似文献

免疫细胞衍生的GRM4负向调节抗肿瘤免疫反应。在本研究中,我们报道了代谢型谷氨酸受体4(GRM4)在抑制抗肿瘤免疫中的新作用。我们在三个小鼠同基因肿瘤模型(B16、MC38和3LL)中发现,基因敲除(Grm4−/−)或药物抑制都会导致肿瘤生长显著延迟。从机制上讲,GRM4的干扰通过促进自然杀伤细胞(NK)、CD4+和CD8+T细胞向激活的、增殖的和功能性的表型转变,从而导致强大的抗肿瘤免疫。单细胞RNA测序和T细胞受体分析进一步确定了CD8+T细胞的克隆性增殖和免疫格局的变化。我们进一步证明,Grm4−/−通过环腺苷3‘,5’-单磷酸(CAMP)/cAMP反应元件结合蛋白介导的途径内在地激活CD8+T细胞产生干扰素-γ。我们的研究似乎具有临床意义,因为NKHigh-GRM4low和CD8High-GRM4low与提高黑色素瘤患者的存活率相关。靶向GRM4代表了癌症免疫治疗的一种新方法。
Immune cell–derived GRM4 negatively modulates antitumor immune response. In this study, we report a novel role of metabotropic glutamate receptor 4 (GRM4) in suppressing antitumor immunity. We revealed in three murine syngeneic tumor models (B16, MC38, and 3LL) that either genetic knockout (Grm4−/−) or pharmacological inhibition led to significant delay in tumor growth. Mechanistically, perturbation of GRM4 resulted in a strong antitumor immunity by promoting natural killer (NK), CD4+, and CD8+ T cells toward an activated, proliferative, and functional phenotype. Single-cell RNA sequencing and T cell receptor profiling further defined the clonal expansion and immune landscape changes in CD8+ T cells. We further showed that Grm4−/− intrinsically activated interferon-γ production in CD8+ T cells through cyclic adenosine 3′,5′-monophosphate (cAMP)/cAMP response element binding protein–mediated pathway. Our study appears to be of clinical significance as a signature of NKhigh-GRM4low and CD8high-GRM4low correlated with improved survival in patients with melanoma. Targeting GRM4 represents a new approach for cancer immunotherapy.
DOI: 10.1038/nature20554
发表时间: 2016-11-17
期刊: Nature
影响因子: 64.8
作者:
De Henau O;Rausch M;Winkler D;Campesato LF;Liu C;Cymerman DH;Budhu S;Ghosh A;Pink M;Tchaicha J;Douglas M;Tibbitts T;Sharma S;Proctor J;Kosmider N;White K;Stern H;Soglia J;Adams J;Palombella VJ;McGovern K;Kutok JL;Wolchok JD;Merghoub T
通讯作者: Merghoub T
DOI: 10.1158/2159-8290.cd-19-0154
发表时间: 2019-11-01
期刊: CANCER DISCOVERY
影响因子: 28.2
作者:
Kansara, Maya;Thomson, Kristian;Thomas, David M.
通讯作者: Thomas, David M.
DOI: 10.1016/j.neulet.2015.08.038
发表时间: 2015-10-08
影响因子: 2.5
作者:
Li, Jing;Meng, Huaqing;Qiu, Tian
通讯作者: Qiu, Tian
DOI: 10.1016/j.cell.2018.02.052
发表时间: 2018-04-05
期刊: Cell
影响因子: 64.5
作者:
Liu J;Lichtenberg T;Hoadley KA;Poisson LM;Lazar AJ;Cherniack AD;Kovatich AJ;Benz CC;Levine DA;Lee AV;Omberg L;Wolf DM;Shriver CD;Thorsson V;Cancer Genome Atlas Research Network;Hu H
通讯作者: Hu H
DOI: 10.1523/jneurosci.0118-06.2006
发表时间: 2006-04-19
影响因子: 5.3
作者:
Jiang, Q;Yan, Z;Feng, J
通讯作者: Feng, J